Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

Author's Avatar
Mar 12, 2022

RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP, Financial) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share.